Start-Up Spotlight: Embolx Believes Balloon Microcatheter Occlusion Will Be A 'Breakthrough' For BPH, Cancer
Executive Summary
Embolx is having a big year. US FDA cleared its Sniper balloon occlusion microcatheter for pressure-directed arterial embolization a few months after the UK's NICE issued recommendations supporting prostate artery embolization for lower urinary tract symptoms caused by benign prostatic hyperplasia. Now the company is focused on improving market penetration by investing in physician-education and supporting research on new applications of targeted embolization, hoping to attract commercial partners or a possible acquirer.